Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 19 phantom stock units through the company's Supplemental Savings Plan.
Summary
- On June 14, 2024, Albert Bourla, Chairman & CEO of Pfizer Inc., acquired 19 phantom stock units through the Pfizer Supplemental Savings Plan (SSP).
- The price of each phantom stock unit was $27.53.
- Following the transaction, Bourla directly owns 669,366 shares of Pfizer common stock.
- These units are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing reporting an insider transaction. It doesn't inherently convey positive or negative sentiment.
Positives
- The acquisition of phantom stock units by the CEO demonstrates his continued investment in the company's future.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the investment activities of company executives.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it involves phantom stock units and is part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of transaction: Albert Bourla acquired 19 phantom stock units. |
| 06/17/2024 | Date of signature on the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.